Elezanumab (ABT-555)
Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries and acute ischemic stroke.
Type of Molecule
BiologicTarget
RGMaProduct Type
New Indication| Potential Indication | Region | Phase (1, 2, 3, Submitted) |
|---|---|---|
| Spinal Cord Injury | n/a |
Phase 2
|
| Acute Ischemic Stroke | n/a |
Phase 2
|